MCID: NRG005
MIFTS: 27

Neurogenic Hypertension malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Neurogenic Hypertension

About this section

Aliases & Descriptions for Neurogenic Hypertension:

Name: Neurogenic Hypertension 47 67

Classifications:



Summaries for Neurogenic Hypertension

About this section
MalaCards based summary: Neurogenic Hypertension is related to neuronitis and cervicitis, and has symptoms including cushingoid facies An important gene associated with Neurogenic Hypertension is ACE2 (Angiotensin I Converting Enzyme 2), and among its related pathways are Peptide hormone metabolism and Agents Acting on the Renin-Angiotensin System Pathway, Pharmacodynamics. Affiliated tissues include brain, kidney and spinal cord.

Related Diseases for Neurogenic Hypertension

About this section

Diseases related to Neurogenic Hypertension via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
idRelated DiseaseScoreTop Affiliating Genes
1neuronitis9.8
2cervicitis9.8
3obesity9.7
4cerebritis9.7
5neuroma biliary tract9.5ACE2, ENPEP
6atherosclerosis9.5
7sleep apnea9.5
8obstructive sleep apnea9.5
9renal hypertension9.5
10cerebral atherosclerosis9.5
11porphyria9.5
12thyroiditis9.5
13hypoxia9.5
14syncope9.5

Graphical network of diseases related to Neurogenic Hypertension:



Diseases related to neurogenic hypertension

Symptoms for Neurogenic Hypertension

About this section

UMLS symptoms related to Neurogenic Hypertension:


cushingoid facies

Drugs & Therapeutics for Neurogenic Hypertension

About this section

Drugs for Neurogenic Hypertension (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 24)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1Anti-Infective AgentsPhase 3, Phase 1, Phase 221402
2Antibiotics, AntitubercularPhase 36972
3Anti-Bacterial AgentsPhase 3, Phase 1, Phase 210884
4carnitineNutraceuticalPhase 3158
5Omega 3 Fatty AcidNutraceuticalPhase 3969
6
FesoterodineapprovedPhase 260286930-02-7, 286930-03-86918558
Synonyms:
FESO
 
Fesoterodine
Toviaz
7
Minocyclineapproved, investigationalPhase 1, Phase 222410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
8Cholinergic AntagonistsPhase 21658
9Neurotransmitter AgentsPhase 2, Early Phase 117734
10Cholinergic AgentsPhase 23846
11Muscarinic AntagonistsPhase 21134
12
Yohimbineapproved, vet_approvedEarly Phase 127146-48-58969
Synonyms:
(+)-Yohimbin
(+)-Yohimbine
(+)-yohimbine
(16alpha,17alpha)-17-Hydroxy-yohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-Hydroxyyohimban-16-carboxylic acid methyl ester
(16alpha,17alpha)-17-hydroxyyohimban-16-carboxylic acid methyl ester
146-48-5
17-Hydroxy-yohimbane-16-carboxylic acid methyl ester
17-Hydroxyyohimban-16-carboxylic acid methyl ester
17alpha-Hydroxyyohimban-16alpha-carboxylic acid methyl ester
17alpha-hydroxyyohimban-16alpha-carboxylic acid methyl ester
2-Hydroxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydro-indolo[2',3':3,4]pyrido[1,2-b]isoquinoline-1-carboxylic acid methyl ester
4-25-00-01237 (Beilstein Handbook Reference)
65-19-0
AC1L1S1D
APHRODINE
Actibine
Aphrodine
Aphrodyne
Aphrosol
BCBcMAP01_000032
BPBio1_000472
BRD-K35586044-001-02-6
BRD-K35586044-003-03-0
BRN 0097276
BSPBio_000428
BSPBio_001236
Baron-X
Benz[g]indolo[2,3-a]quinolizine, yohimban-16-carboxylic acid deriv.
Bio1_000455
Bio1_000944
Bio1_001433
Bio2_000458
Bio2_000938
C09256
CHEBI:10093
CHEMBL15245
CID8969
Corynine
D08685
DB01392
Dayto himbin
EINECS 205-672-0
HMS1362N17
HMS1792N17
HMS1990N17
HMS2089G19
I14-13374
IDI1_002213
 
InChI=1/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12?,15?,17?,18-,19+/m0/s
Johimbin
KBio2_000576
KBio2_003144
KBio2_005712
KBio3_001031
KBio3_001032
KBioGR_000576
KBioSS_000576
LS-162738
Lopac0_001210
MLS000728591
MLS001333983
MolPort-001-794-653
NCGC00025018-05
NCGC00025018-06
NCGC00025018-07
NSC19509
Prestwick0_000584
Prestwick1_000584
Prestwick2_000584
Prestwick3_000584
Quebrachin
Quebrachine
SMP1_000320
SMR000058527
SMR000470778
SPBio_002647
STOCK1N-51304
Thybine
UNII-2Y49VWD90Q
Yocon
Yohimar
Yohimban-16-.alpha.-carboxylic acid, 17-.alpha.-hydroxy-, methyl ester
Yohimban-16-alpha-carboxylic acid, 17-alpha-hydroxy-, methyl ester
Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- (9CI)
Yohimban-16alpha-carboxylic acid, 17alpha-hydroxy-, methyl ester (8CI)
Yohimbic acid methyl ester
Yohimbin
Yohimbine
Yohimbine (DCF)
Yohimbol-16alpha-carboxylic acid, methyl ester (6CI)
Yohimex
Yoman
Yovital
methyl (16alpha,17alpha)-17-hydroxyyohimban-16-carboxylate
methyl 17alpha-hydroxyyohimban-16alpha-carboxylate
nchembio.188-comp13
nchembio705-2
trans-Quinolizidine yohimbine
13
Melatoninapproved, nutraceutical, vet_approvedEarly Phase 125573-31-4896
Synonyms:
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-Methoxy-N-acetyltryptamine
5-methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
AKOS000276269
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
BAS 01281092
BIDD:ER0618
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
Bio-0635
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
CID896
ChemDiv2_003916
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
LS-1623
Lopac-M-5250
Lopac0_000787
M 5250
M-1200
M-1250
M1105
M5250_SIGMA
ML1
MLS000859594
MLS001055382
MLS001240204
MT6
Mela-T
Melapure
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
 
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
Melovine
MolPort-000-737-883
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-Acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine Melatonine
N-Acetyl-5-methoxytryptamine
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-Acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-acetyl-5-methoxy-tryptamine
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Nature'S Harmony
Night Rest
Oprea1_104553
Oprea1_814234
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Pineal Hormone
Posidorm
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
Prestwick_312
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
SPECTRUM1500690
STK386880
Sleep Right
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
Spectrum_000185
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide
14MydriaticsEarly Phase 1763
15Protective AgentsEarly Phase 17190
16Central Nervous System DepressantsEarly Phase 112806
17Peripheral Nervous System AgentsEarly Phase 122776
18Adrenergic AgentsEarly Phase 15140
19Adrenergic alpha-AntagonistsEarly Phase 1727
20Adrenergic AntagonistsEarly Phase 11535
21Antihypertensive AgentsEarly Phase 14095
22Autonomic AgentsEarly Phase 19774
23AntioxidantsEarly Phase 12928
24YohimbeNutraceuticalEarly Phase 127

Interventional clinical trials:

idNameStatusNCT IDPhase
1Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in ChildrenUnknown statusNCT02192580Phase 3
2L-carnitine on the Prevention of Renal Scarring in Acute PyelonephritisUnknown statusNCT02007889Phase 3
3Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive PatientsRecruitingNCT02133885Phase 1, Phase 2
4Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)RecruitingNCT02676154Phase 2
5Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive PatientsRecruitingNCT02133872Phase 1
6Study 3: Minocycline Decreases Microglia ActivationNot yet recruitingNCT02213575Phase 1
7Adolescent Blood Pressure Variation and Ventricular MassCompletedNCT00005200
8Brain fMRT In Takotsubo CardiomyopathyRecruitingNCT02240056
9Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic HypotensionNot yet recruitingNCT02963181Early Phase 1

Search NIH Clinical Center for Neurogenic Hypertension

Genetic Tests for Neurogenic Hypertension

About this section

Anatomical Context for Neurogenic Hypertension

About this section

MalaCards organs/tissues related to Neurogenic Hypertension:

35
Brain, Kidney, Spinal cord, Medulla oblongata, Hypothalamus, Heart, Pons

Animal Models for Neurogenic Hypertension or affiliated genes

About this section

Publications for Neurogenic Hypertension

About this section

Articles related to Neurogenic Hypertension:

(show top 50)    (show all 138)
idTitleAuthorsYear
1
Selective Deletion of the Brain-Specific Isoform of Renin Causes Neurogenic Hypertension. (27754863)
2016
2
I+-Lipoic acid reduces neurogenic hypertension by blunting oxidative stress-mediated increase in ADAM17. (26254330)
2015
3
Presympathetic neuron dysfunction--time to reconsider increased intrinsic activity as the cause of neurogenic hypertension. (24987020)
2014
4
Visualizing oxidative stress-induced depression of cardiac vagal baroreflex by MRI/DTI in a mouse neurogenic hypertension model. (23747290)
2013
5
Brain angiotensin-converting enzyme type 2 shedding contributes to the development of neurogenic hypertension. (24014829)
2013
6
Stabilization of hypoxia inducible factor-1I+ ameliorates acute renal neurogenic hypertension. (24309492)
2013
7
Redox-sensitive oxidation and phosphorylation of PTEN contribute to enhanced activation of PI3K/Akt signaling in rostral ventrolateral medulla and neurogenic hypertension in spontaneously hypertensive rats. (22746319)
2013
8
Actions of rilmenidine on neurogenic hypertension in BPH/2J genetically hypertensive mice. (24275840)
2013
9
Neurogenic hypertension: revelations from genome-wide gene expression profiling. (22639016)
2012
10
Neuroinflammation and oxidative stress in rostral ventrolateral medulla contribute to neurogenic hypertension induced by systemic inflammation. (22958438)
2012
11
Chiari I malformation with neurogenic hypertension: case report. (22890471)
2012
12
Angiotensin-II-induced reactive oxygen species along the SFO-PVN-RVLM pathway: implications in neurogenic hypertension. (21755262)
2011
13
Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. (19926873)
2010
14
Neurogenic hypertension. (20407134)
2010
15
Transcriptional upregulation of mitochondrial uncoupling protein 2 protects against oxidative stress-associated neurogenic hypertension. (19762685)
2009
16
Is neurogenic hypertension related to vascular inflammation of the brainstem? (18585782)
2009
17
Signalling across the blood brain barrier by angiotensin II: novel implications for neurogenic hypertension. (18443753)
2008
18
Neurovascular compression of the medulla: can it cause neurogenic hypertension? (17215662)
2007
19
Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. (17519130)
2007
20
Reduction in molecular synthesis or enzyme activity of superoxide dismutases and catalase contributes to oxidative stress and neurogenic hypertension in spontaneously hypertensive rats. (16716903)
2006
21
Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. (12052849)
2002
22
Unloading arterial baroreceptors causes neurogenic hypertension. (11893608)
2002
23
The role of MRI in screening for neurogenic hypertension. (10663483)
2000
24
Microvascular decompression of the left lateral medulla oblongata for severe refractory neurogenic hypertension. (9894990)
1999
25
Neurogenic hypertension. A new MRI protocol for the evaluation of neurovascular compression of the cranial nerves IX and X root-entry zone. (10587874)
1999
26
A limited renal injury may cause a permanent form of neurogenic hypertension. (9657632)
1998
27
Neurogenic hypertension. (8421217)
1993
28
Neurogenic hypertension: etiology and surgical treatment. I. Observations in 53 patients. (3977442)
1985
29
Sympathoadrenal dysfunction in rats with chronic neurogenic hypertension. (3979427)
1985
30
Hemodynamic and neural mechanisms of acute neurogenic hypertension in the rat. (6507647)
1984
31
Central serotonergic activity after neurogenic hypertension. (6832215)
1983
32
Norepinephrine release and vascular response elicited by nerve stimulation in rats with chronic neurogenic hypertension. (6312017)
1983
33
Presynaptic dopamine receptor stimulation and the antihypertensive action of pergolide in experimental neurogenic hypertension. (7122527)
1982
34
Naloxone and acute neurogenic hypertension in anaesthetized dogs. (7138086)
1982
35
Neurogenic hypertension revisited. (7018799)
1981
36
Neurogenic hypertension related to vascular compression of the lateral medulla. (7432603)
1980
37
Plasma prostaglandin E during neurogenic hypertension in tetraplegic man. (1204295)
1975
38
Altered norepinephrine synthesis of splanchnic vessels in neurogenic hypertension. (4152768)
1974
39
Effects of p-chlorophenylalanine on blood pressure and heart rate in normal rabbits and rabbits with neurogenic hypertension. (4282070)
1974
40
Hemodynamic characteristics of chronic experimental neurogenic hypertension in unanesthetized dogs. (5786795)
1969
41
EEG in experimental neurogenic hypertension. (Evaluation with Fourier analysis). (5839145)
1965
42
Neurogenic hypertension. (14420562)
1959
43
Experimental psycho-neurogenic hypertension and its treatment with hydrogenated ergot alkaloids (hydergine). (13339143)
1956
44
The effect of dietary sodium-potassium relations on the experimental renal and neurogenic hypertension of the rat. (13372358)
1956
45
Thyroid gland, gonads and experimental neurogenic hypertension. (13262069)
1955
46
Neurogenic hypertension in man in porphyria: transient hypertension and tachycardia caused by disruption of the carotid sinus; review of buffer nerve mechanism. (13170848)
1954
47
Cortical ablations in dogs with chronic neurogenic hypertension. (13123578)
1954
48
The role of the adrenals in experimental neurogenic hypertension. (13093058)
1953
49
Effect of experimental neurogenic hypertension on renal blood flow and glomerular filtration rates in intact denervated kidneys of unanesthetized rabbits with adrenal glands demedullated. (20268824)
1947
50
THE CIRCULATION IN EXPERIMENTAL NEUROGENIC HYPERTENSION. (16695240)
1945

Variations for Neurogenic Hypertension

About this section

Expression for genes affiliated with Neurogenic Hypertension

About this section
Search GEO for disease gene expression data for Neurogenic Hypertension.

Pathways for genes affiliated with Neurogenic Hypertension

About this section

GO Terms for genes affiliated with Neurogenic Hypertension

About this section

Biological processes related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1angiotensin catabolic process in bloodGO:00020059.4ACE2, ENPEP
2regulation of systemic arterial blood pressure by renin-angiotensinGO:00030819.3ACE2, ENPEP
3angiotensin maturationGO:00020039.1ACE2, ENPEP

Molecular functions related to Neurogenic Hypertension according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1zinc ion bindingGO:00082709.1ACE2, ENPEP
2metallopeptidase activityGO:00082378.8ACE2, ENPEP

Sources for Neurogenic Hypertension

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet